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Abstract
Background: The aim of the publication is to show differences among patients with the first 
detected episode of atrial fibrillation (AF), paroxysmal, and persistent AF patients, for whom 
cardioversion was planned in the hospital setting in Poland.
Methods: We present an analysis of the Polish cohort of the multicenter, multinational 
RHYTHM-AF registry. Consecutive patients in the hospital setting, aged ≥ 18 years, with doc-
umented AF at the time of enrollment, and for whom cardioversion of AF is one of the planned 
therapeutic options were recruited. Follow-up data was collected 60 days after enrollment.
Results: Five-hundred-and-one patients were recruited, 483 with a defined AF type: 88 — 
first detected, 191 paroxysmal, and 204 persistent AF. CHA2DS2VASc scores were not signifi-
cantly different between the groups, while treatment with vitamin K antagonists (VKA) was 
significantly lower in paroxysmal AF group than in persistent AF patients. Primary electrical 
cardioversion was most commonly performed in patients with persistent AF (90.4%), while 
primary pharmacological cardioversion — in the first detected AF (80.0%) and paroxysmal AF 
patients (76.7%). During 2 months of follow-up, the rate of rehospitalization and complications 
was comparable among the groups.
Conclusions: Despite their comparable CHA2DS2VASc scores, patients with persistent AF 
were more frequently treated with VKA antagonists than other groups. Recurrence of AF within 
2 months after restoring sinus rhythm was present in about 25% of the patients, and the rate 
of complications was not different among the three groups. (Cardiol J 2015; 22, 4: 453–458)
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Introduction
Atrial fibrillation (AF) is the most common 
sustained arrhythmia in clinical practice. Its preva-
lence increases with age. It has been estimated 
that over 6 million people in the European Union 
have AF [1]. AF significantly increases the risk of 
stroke and decreases the quality of life [2]. The risk 
of death from AF-related stroke is doubled and the 
cost of care is increased 1.5-fold [1]. The risk of 
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death is increased two times in AF, independently 
of other known predictors of mortality [3].
The natural course of AF starts with the first 
detected episode, then the majority of patients 
AF is paroxysmal and within a few years AF be-
comes persistent (intermitted with cardioversion) 
or permanent (when cardioversion is no longer 
planned) [1].
The aim of our publication is to show differ-
ences among three groups of patients, those with 
the first detected episode of AF, paroxysmal, and 
persistent AF, for whom cardioversion is planned 
in the hospital setting in Poland.
Methods
Study design
RHYTHM-AF is a prospective observational 
study in 10 countries: Australia, Brazil, France, 
Germany, Italy, Netherlands, Poland, Spain, Swe-
den, and the United Kingdom. Patients with recent 
onset AF considered for cardioversion were en-
rolled from participating hospitals and acute care 
centers between May 2010 and June 2011 [4, 5]. 
General characteristics of the Polish population and 
major results have been reported [6, 7]. Here we 
present analysis of the results in Poland by AF type.
Study population
Centers recruiting patients were selected to 
be representative of those treating AF in partici-
pating countries. All patients at least 18 years old 
with documented AF as confirmed by electrocardio-
gram and in whom a cardioversion was one of the 
planned therapeutic options were considered for 
the study. They included patients in whom actions 
were undertaken in anticipation of cardioversion 
(e.g., scheduled cardioversion, anticoagulation, 
oral loading) and for whom informed consent was 
obtained. Only patients who were already enrolled 
in the current trial, enrolled in a separate trial, and 
those with atrial flutter were excluded.
Primary pharmacological cardioversion (PCV) 
was considered successful if sinus rhythm (SR) or 
atrial rhythm was obtained within 24 h after its 
initiation. Primary electrical cardioversion (ECV) 
was defined as successful if SR was obtained and 
maintained for at least 10 min after the last shock. 
The definitions of first detected episode, paroxys-
mal and persistent AF were according to current 
guidelines [1].
All patient data were collected via a remote 
web-based data collection form using the multi-
lingual software solution EBogen© developed by 
the IHF Ludwigshafen, Germany (the coordinating 
center for the study).
Statistical analysis
All data are presented as mean and standard 
deviation, median and interquartile range or num-
ber and percentage of the population, depending on 
the characteristic of the parameter. All comparisons 
were made using c2 or Mann-Whitney-Wilcoxon 
tests. Because of multiple comparisons (about 50) 
Bonferroni correction was applied, we considered 
a p value < 0.001 statistically significant.
Results
Five-hundred-and-one patients were included 
in the analysis, 483 of whom had a defined AF type: 
88 had the first detected episode of AF, 191 parox-
ysmal AF, and 204 persistent AF. The character-
istics of the study group, stratified by AF type are 
shown in Table 1. Patients with persistent AF were 
younger and less frequently female. Concomitant 
diseases were not different except for history of 
heart failure (most frequent in patients with per-
sistent AF). CHA2DS2VASc scores were slightly 
different among the three groups, with the lowest 
scores in persistent AF patients. Treatment with 
vitamin K antagonists (VKA) was significantly less 
frequently applied in the paroxysmal AF group than 
in the persistent AF patients. AF as the primary 
reason for admission was less frequent in the first 
detected episode group — in this group acute coro-
nary syndrome as the primary reason for admission 
was more frequent than in other groups.
An overview of the AF characteristics is 
shown in Table 2. A lack of AF symptoms was most 
common in persistent AF (20.1%), on the other 
extreme, only 6.8% of patients with paroxysmal AF 
had no symptoms. Palpitations and chest pain were 
most prevalent in the paroxysmal AF group, while 
fatigue — in persistent AF. The mean frequency 
of dizziness was 9.2% in the whole cohort and was 
not significantly different among groups.
Selected additional parameters are shown in 
Table 3. Notably potassium level was significantly 
different among groups, with the highest value in per-
sistent AF patients (still potassium level was within 
normal range among the three groups of patients).
Cardioversion data are shown in Table 4. Time 
to first cardioversion was the longest in persistent 
AF patients. Primary ECV was applied to the 
highest proportion of patients with persistent AF 
(90.4%), while primary PCV — to first-detected 
AF (80.0%) and paroxysmal AF patients (76.7%). 
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Table 1. Baseline characteristics of the registry group.
Total  
(n = 501)
First detected 
(n = 88)
Paroxysmal  
(n = 191)
Persistent  
(n = 204)
P
Age* 64.2 ± 12.1 65.2 ± 13.2 66.8 ± 12.0 61.9 ± 11.4 < 0.0001
Women 193 (38.5) 36 (40.9) 92 (48.2) 59 (28.9) < 0.001
BMI* 29.1 ± 4.6 29.2 ± 5.1 28.6 ± 4.3 29.6 ± 4.6 0.22
Hypertension 375 (75.0) 65 (73.9) 153 (80.5) 144 (70.6) 0.07
Diabetes 104 (20.8) 22 (25.0) 34 (17.8) 41 (20.1) 0.38
Hyperlipidemia 238 (52.3) 38 (48.7) 91 (54.5) 102 (52.8) 0.70
Previous MI 80 (16.0) 14 (15.9) 36 (18.8) 28 (13.7) 0.38
Heart failure 120 (24) 10 (11.4) 36 (18.8) 64 (31.4) < 0.001
Valvular heart disease 90 (18.5) 9 (10.6) 28 (15.5) 45 (22.2) < 0.05
CHADS2 score* 1.5 ± 1.0 1.4 ± 1.1 1.5 ± 1.0 1.4 ± 0.9 0.59
CHA2DS2-VASc score* 2.7 ± 1.7 2.6 ± 1.7 3.0 ± 1.8 2.3 ± 1.5 < 0.01
VKA treatment 294 (58.7) 7 (8.0) 101 (52.9) 175 (85.8) < 0.0001
Ventricular rate  
at enrollment**
105  
(86–130)
120  
(100–140)
120  
(100–130)
90  
(75–110)
< 0.0001
Primary reason for admission:
AF 403 (80.4) 55 (62.5) 158 (82.7) 176 (86.3) < 0.0001
ACS 23 (4.6) 14 (15.9) 7 (3.7) 2 (1.0) < 0.0001
*Mean ± standard deviation; **Median (interquartile range); data are shown as numbers (%); AF — atrial fibrillation; ACS — acute coronary 
syndrome; BMI — body mass index; MI — myocardial infarction; VKA — vitamin K antagonists
Table 2. Atrial fibrillation (AF) characteristics of the registry group.
Total  
(n = 501)
First  
detected  
(n = 88)
Paroxysmal  
(n = 191)
Persistent  
(n = 204)
P
Time since first  
AF episode*
1,201.5  
(269.0–3,551.0)
NA 1,423.0  
(423.0–3,993.0)
988.0  
(237.5–2,748.0)
NA
Duration of  
current episode*
1.0  
(0.0–58.0)
0.0  
(0.0–2.0)
0.0  
(0.0–1.0)
79.5  
(32.5–211.5)
< 0.0001
Symptoms:
No symptoms of AF 71 (14.2) 13 (14.8) 13 (6.8) 41 (20.1) < 0.001
Shortness of breath 157 (31.3) 29 (33.0) 55 (28.8) 65 (31.9) 0.72
Fatigue 197 (39.3) 23 (26.1) 61 (31.9) 108 (52.9) < 0.0001
Palpitations 317 (63.3) 54 (61.4) 150 (78.5) 105 (51.5) < 0.0001
Chest pain 84 (16.8) 20 (22.7) 46 (24.1) 13 (6.4) < 0.0001
Dizziness 46 (9.2) 8 (9.1) 21 (11.0) 16 (7.8) 0.56
*Median (interquartile range); data are shown as numbers (%); NA — not applicable
Table 3. Additional tests (echocardiography, laboratory measurements).
Total  
(n = 501)
First detected  
(n = 88)
Paroxysmal  
(n = 191)
Persistent  
(n = 204)
P
Potassium 4.3 (4.0–4.6) 4.2 (3.9–4.6) 4.2 (3.9–4.5) 4.4 (4.1–4.6) < 0.001
TSH 1.4 (0.8–2.1) 1.2 (0.8–1.6) 1.3 (0.7–2.1) 1.4 (1.0–2.3) < 0.05
LA [mm] 44.0 (40.0–47.0) 43.0 (38.0–46.0) 43.0 (38.0–46.0) 45.0 (41.0–47.0) < 0.05
LVEF < 45%* 73/358 (20.4) 16/77 (20.8) 12/112 (10.7) 37/154 (24.0) < 0.05
*Number/number of patients with echocardiography data (%); data are shown as median (interquartile range) or number (%); LA — left 
atrium, LVEF — left ventricular ejection fraction; TSH — thyroid-stimulating hormone
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Table 4. Cardioversion details and reasons for no cardioversion attempt.
Total  
(n = 294)
First detected  
(n = 55)
Paroxysmal  
(n = 116)
Persistent  
(n = 115)
P
Patients with any CV 294 (58.7) 55 (62.5) 116 (60.7) 115 (56.4) 0.53
Time to first CV [h]* 9:55  
(1:48–30:37)
4:07  
(1:17–27:28)
2:29  
(0:43–22:20)
24:25  
(8:42–40:14)
< 0.0001
Primary ECV 148 (50.3) 11 (20.0) 27 (23.3) 104 (90.4) < 0.0001
Primary ECV successful 131 (88.5) 11 (100) 24 (88.9) 90 (86.5) 0.42
Primary PCV 146 (49.7) 44 (80.0) 89 (76.7) 11 (9.6) < 0.0001
Primary PCV successful 110 (75.3) 39 (88.6) 64 (71.9) 6 (54.5) <0.05
No CV attempt n = 207 n = 33 n = 75 n = 89
Reasons**:
Spontaneous SR 55 (26.6) 12 (36.4) 37 (49.3) 5 (5.6) < 0.0001
Left atrial thrombus 16/124 (13.7) 1/4 (25.0) 0 (0.0) 14/79 (17.7) < 0.05
Spontaneous echocontrast 5 (2.4) 0 (0.0) 0 (0.0) 5 (5.6) < 0.05
Size of LA 8 (3.9) 0 (0.0) 1 (1.3) 4 (4.5) 0.26
Duration of AF uncertain 27 (13.0) 10 (30.3) 3 (4.0) 13 (14.6) < 0.001
Planned CV after discharge 92 (44.4) 16 (48.5) 24 (32.0) 51 (57.3) < 0.01
Refused by patient 6 (2.9) 1 (3.0) 1 (1.3) 2 (2.2) 0.83
Procedure expected  
to be ineffective
13 (6.3) 0 (0.0) 2 (2.7) 7 (7.9) 0.11
Other reason 26 (12.6) 5 (15.2) 9 (12.0) 10 (11.2) 0.89
*Median (interquartile range); **Choosing more than one option was available; data are shown as numbers (%); AF — atrial fibrillation;  
CV — cardioversion; ECV — electrical cardioversion; LA — left atrium; PCV — pharmacological cardioversion; SR — sinus rhythm
Table 5. Discharge and follow-up data.
Total  
(n = 501)
First detected  
(n = 88)
Paroxysmal  
(n = 191)
Persistent  
(n = 204)
P
Duration of hospital stay [h]* 69:00  
(27:25–120:20)
75:22  
(43:34–157:14)
67:18  
(12:12–93:04)
68:17  
(48:52–121:20)
< 0.001
VKA treatment at discharge 388 (77.4%) 37 (42.0%) 142 (74.3%) 194 (95.1%) < 0.0001
Amiodarone at discharge 71 (14.2%) 8 (9.1%) 23 (12.0%) 38 (18.6%) 0.05
Propafenone at discharge 106 (21.2%) 12 (13.6%) 53 (27.7%) 40 (19.6%) < 0.05
Sotalol at discharge 24 (4.8%) 0 (0.0%) 14 (7.3%) 9 (4.4%) < 0.05
Rhythm at discharge — SR 348 (69.5%) 65 (73.9%) 161 (84.3%) 114 (55.9%) < 0.0001
Rhythm at discharge — AF 140 (27.9%) 20 (22.7%) 25 (13.1%) 86 (42.2%) < 0.0001
Follow-up:
Current rhythm — SR 352 (71.0%) 67 (77.0%) 162 (85.7%) 114 (56.4%) < 0.0001
Current rhythm — AF 137 (27.6%) 19 (21.8%) 26 (13.8%) 84 (41.6%) < 0.0001
Recurrence of AF 127 (25.4%) 12 (13.6%) 67 (35.1%) 47(23.2%) < 0.001
Rehospitalization 96 (19.2%) 13 (14.8%) 53 (27.7%) 29 (14.3%) < 0.01
VKA treatment 382 (76.6%) 33 (37.5%) 142 (74.7%) 192 (94.6%) < 0.0001
Aspirin 149 (29.9%) 53 (60.2%) 53 (27.9%) 39 (19.3%) < 0.0001
Clopidogrel 41 (8.2%) 19 (21.6%) 11 (5.8%) 11 (5.4%) < 0.0001
Amiodarone 70 (14.0%) 9 (10.2%) 22 (11.6%) 37 (18.2%) 0.09
Propafenone 102 (20.4%) 11 (12.5%) 53 (27.9%) 37 (18.2%) < 0.01
Sotalol 24 (4.8%) 0 (0.0%) 13 (6.8%) 10 (4.9%) < 0.05
*Median (interquartile range); AF — atrial fibrillation; SR — sinus rhythm; VKA — vitamin K antagonists
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Spontaneous occurrence of SR was most prevalent 
in the paroxysmal AF group (almost 50% of the 
patients that had not undergone cardioversion, 
19.1% of the whole group of paroxysmal AF), while 
it was present in only 2.5% of the whole group of 
persistent AF.
Discharge and follow-up data are shown in 
Table 5. Hospital stay was the longest in patients 
with the first detected episode of AF. SR at dis-
charge was most common in the paroxysmal AF 
group (84.3%), and the least common in the persis-
tent AF (55.9%). VKA treatment at discharge was 
most common in the persistent AF group. After 
2 months of follow-up the trends in SR maintenance 
and in VKA treatment were the same. Of note is 
that treatment with VKA markedly increased in all 
three groups (first detected, paroxysmal, and per-
sistent AF) comparing baseline vs. discharge and 
follow-up. Patients with the first detected episode 
had the highest frequency of aspirin and clopidogrel 
treatment. Treatment with antiarrhythmic IC and 
class III drugs was not different among group. 
The rate of rehospitalization was comparable, with 
a trend towards a higher frequency in paroxysmal 
AF (more than 25% of patients within 2 months). 
Recurrence of AF was most common in patients 
with paroxysmal AF (35.1%), and the least frequent 
in patients with the first detected episode of AF 
(13.6%).
The rate of adverse events during hospitaliza-
tion was comparable among the three groups, with 
sporadic events like myocardial infarction, pulmo-
nary embolism, transient ischemic attack, or heart 
failure (1 or 2 patients in the whole group). During 
the 2 months of follow-up the overall frequency of 
adverse events was low, with 3 strokes, 5 bleeding 
incidents, and 5 incidents of heart failure, with no 
differences among the groups.
Discussion
The multicenter, prospective RHYTHM AF 
registry has demonstrated that cardioversion of AF 
in real-life patients has a high success rate. The char-
acteristics of the whole Polish cohort of RHYTHM 
AF registry has been published before [5, 6]. Here 
we looked for possible differences among three 
subgroups of these patients, the ones with the first 
detected, paroxysmal, and persistent AF.
The foremost difference was the one in the 
VKA treatment. The distribution of risk factors 
was almost uniform among analyzed subtypes 
of AF, but the patients with persistent AF were 
younger and the prevalence of men over women 
was much higher than in the other groups — that 
explains why despite the same CHADS2 score, 
there was a trend towards a lower CHA2DS2-VASc 
score in the persistent AF patients. They were also 
significantly more frequently treated with VKA 
than the paroxysmal AF patients were. Based on 
the CHA2DS2-VASc score (mean value 2.3 ± 1.5) 
one can assume that persistent AF patients were 
treated correctly, but the paroxysmal AF patients 
were markedly undertreated with VKA. A similar 
trend was observed in the Polish cohort of the 
RecordAF registry [8]. The difference between the 
rhythm control and rate control strategy patients 
in their CHADS2 score (score 2 or more: 31.1% 
vs. 47.8% respectively) was much lower than the 
difference in the VKA treatment frequency (40.3% 
vs. 80.4%). Such a phenomenon has already been 
observed in the Euro Heart Survey on Atrial 
Fibrillation — physicians tend to weigh the per-
ceived AF burden when deciding on antithrombotic 
treatment [9]. This strategy (i.e., refraining from 
antithrombotic treatment) is discouraged by the 
current guidelines but the problem persists. In our 
cohort, treatment with VKA in all groups is mark-
edly higher comparing baseline vs. discharge and 
follow-up — this might suggest that physicians in 
the hospitals are more adherent to the guidelines 
than cardiologists in the outpatient clinics.
Another important difference among the pa-
tients with first detected, paroxysmal, and persis-
tent AF was in the symptoms of AF. About 20% of 
patients with persistent AF showed no symptoms 
of AF, as opposed to only 6% of patients with 
paroxysmal AF. Those results resemble closely 
the ones reported in RecordAF registry — in the 
group of rhythm control strategy 92.4% of patients 
had symptoms, while in the group of rate control 
strategy — 81.5% [8]. Nevertheless, these data 
still should be interpreted with caution: symptom-
atic patients are substantially more likely to be 
admitted to the hospital to undergo cardioversion.
Palpitations and chest pain were frequent in 
the patients with the first detected episode and 
those with paroxysmal AF, while fatigue was re-
ported by about half of the patients with persistent 
AF. Compared to the present cohort, in a large ret-
rospective analysis of patients with AF consulted in 
an Emergency Department, the frequency of chest 
pain was comparable (15%), shortness of breath 
was slightly less common (20.7% vs. 31.3% in our 
cohort), while frequency of fatigue was four times 
less common (9.4% vs. 39.3%) [10].
As could be expected, pharmacological car-
dioversion was the most common option used in 
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paroxysmal and first detected AF, while ECV — in 
persistent AF. This is in agreement with the cur-
rent guidelines [1] and the results of Euro Heart 
Survey [11]. Spontaneous SR restoration was re-
ported in about 20% of patients with paroxysmal 
AF, while only in 2.5% of patients with persistent 
AF. Since the first detected episode of AF could be 
paroxysmal or persistent, the frequency of sponta-
neous SR restoration in that group was somewhere 
between those for paroxysmal and persistent 
groups — almost 14%. Those rates were similar 
to the ones published so far [12, 13].
Patients with the first detected episode of AF 
had a longer hospital stay and a higher frequency 
of aspirin and clopidogrel use — acute coronary 
syndrome as a triggering factor and the primary 
cause of hospitalization was relatively common in 
those patients.
At discharge SR was present in about 70% 
of all patients, but in only 55.9% of patients with 
persistent AF. During 2 months of follow-up recur-
rence of AF was observed in about 25% of patients 
— the rate comparable to previous results [14], and 
the frequency of rehospitalization was about 19% in 
the whole group (27.7% in the paroxysmal AF) — in 
one of the earlier studies 33–35% of patients had 
recurrent visits on Emergency Department during 
a 6-months of follow-up [15]. In the Euro Heart 
Survey on Atrial Fibrillation registry, the rate of 
rehospitalization within 1 year was between 41% 
(first detected AF episode) and 54% (paroxysmal 
AF) [9].
Limitations of the study
Small sample size and crude, unadjusted 
analyses are the major limitations of our study. 
Follow-up period was very short (the registry was 
planned majorly for baseline and hospitalization 
characteristics of patients with AF for whom car-
dioversion was planned). The observations should 
be therefore interpreted with caution.
Conclusions
Patients with persistent AF were younger 
and the ratio of men to women was significantly 
higher than in other groups. Despite comparable 
CHA2DS2-VASc scores, patients with persistent 
AF were at all time-points (admission, discharge, 
follow-up) more frequently treated with VKA 
antagonists than the other groups were. Primary 
ECV was most commonly applied to patients with 
persistent AF, primary PCV — to first detected 
AF and paroxysmal AF patients. Recurrence of AF 
within 2 months after restoring SR was present 
in about 25% of the patients, and even in the first 
detected episode group it occurred in more than 
10% of patients. The results show that in an un-
selected group of patients with AF, anticoagulant 
treatment is still substantially less common than 
recommended by current guidelines.
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